Certain gene variations in the ghrelin gene are associated with obesity, type 2 diabetes, metabolic syndrome, MAFLD, and hepatocellular carcinoma
Against placebo, the label reports nausea in 44% versus 16%, diarrhea in 30% versus 16%, vomiting in 24% versus 6%, and constipation in 24% versus 11%
That is why many clinicians and researchers see potential synergy
Bulletin of Experimental Biology and Medicine, 134(3), 251-253
Heterogeneity in the analyses vs active comparators could be attributed to differences in efficacy between the two GLP-1 RAs comparators (dulaglutide and semaglutide) or to differences in background glucose-lowering therapy between the two trials with basal insulin